Targeting treatment-resistant breast cancer stem cells with FKBPL and its peptide derivative, AD-01, via the CD44 pathway.
McClements L, Yakkundi A, Papaspyropoulos A, Harrison H, Ablett MP, Jithesh PV, McKeen HD, Bennett R, Donley C, Kissenpfennig A, McIntosh S, McCarthy HO, O'Neill E, Clarke RB, Robson T.
McClements L, et al. Among authors: donley c.
Clin Cancer Res. 2013 Jul 15;19(14):3881-93. doi: 10.1158/1078-0432.CCR-13-0595. Epub 2013 Jun 5.
Clin Cancer Res. 2013.
PMID: 23741069